Tag Archives: Lilly
By William Looney | Published: January 30, 2013
Eli Lilly thinks so, with a new “back to school” pathway on stakeholder engagement Monday, February 4, is World Cancer Day. Eli Lilly & Co., one of big Pharma’s biggest, has decided to give the moment its due with the launch of a new policy advocacy initiative to ensure that patients actually benefit from the [...]
By Ben Comer | Published: June 11, 2012
Following his keynote address last week at the Financial Times US Healthcare and Life Sciences Conference in New York, Eli Lilly CEO John Lechleiter huddled into a corridor to speak with PharmExec about his agenda as incoming chairman of PhRMA, and how to fix innovation.
By Ben Comer | Published: May 7, 2012
The news that Roche scrapped development on its CETP inhibitor dalcetrapib, a drug designed to raise HDL cholesterol in the blood, likely presages the shuttering of Lilly’s development program for its CETP inhibitor, evacetrapib, industry experts and analysts say.
By admin | Published: January 15, 2010
Image by American Red Cross via Flickr It’s been less than three days since new broke of a massive earthquake in Haiti that all but leveled the struggling country. With thousands dead, a devastated infrastructure, and no emergency plan, countries and businesses around the world have joined in the effort to help the Haitian people with [...]
By admin | Published: August 19, 2009
Image by go elsewhere… via Flickr Lilly, on Wednesday, announced that it would not seek regulatory approval for its osteoporosis treatment arzoxifene, because the drug failed to meet certain end points in Phase III clinical trials. The good news is that the drug was successful in meeting the primary end point of the trial, dubbed â€œGENERATIONS.â€ [...]